Affiliation:
1. Dipartimento di Farmacia-Scienze del Farmaco, Campus “E. Quagliariello”, University of Bari Aldo Moro, Via E. Orabona 4, 70126 Bari, Italy
Abstract
In this study, we report the synthesis of 3-((2-(4-chloro-5-ethoxy-2-nitrophenoxy)acetamido)methyl)phenyl-dimethylcarbamate, designed on the basis of the structures of the commercial acetylcholinesterase inhibitor drug rivastigmine and a substituted aryloxyacetic acid, aiming at a multi-target approach to the therapy of Alzheimer’s disease. The hybrid was obtained thanks to a synthesized intermediate by-product. The compound was fully characterized by using 1H and 13C NMR, FT-IR and HRMS.
Funder
Unione Europea—Next Generation EU
Reference9 articles.
1. Oxidative Stress and the Amyloid Beta Peptide in Alzheimer’s Disease;Cheignon;Redox Biol.,2018
2. Biomarkers for Alzheimer’s Disease: Current Status and Prospects for the Future;Blennow;J. Intern. Med.,2018
3. Leuci, R., Simic, S., Carrieri, A., Chaves, S., La Spada, G., Brunetti, L., Tortorella, P., Loiodice, F., Laghezza, A., and Catto, M. Rivastigmine Structure-Based Hybrids as Potential Multi-Target Anti-Alzheimer’s Drug Candidates, Submitted.
4. Structure-Based Design of Novel Donepezil-like Hybrids for a Multi-Target Approach to the Therapy of Alzheimer’s Disease;Brunetti;Eur. J. Med. Chem.,2022
5. Nucleophilic Aromatic Substitution (SNAr) and Related Reactions of Porphyrinoids: Mechanistic and Regiochemical Aspects;Sample;Eur. J. Org. Chem.,2021